Sugi Predict

Sugi Predict / Compounds / SCHEMBL2597375

SCHEMBL2597375

SCHEMBL2597375

CCOC(=O)N(n1c(=O)[nH]c2cc(CC)c(-c3ccnn3C)cc2c1=O)S(C)(=O)=O

nearest known ligand 0.33

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ HAVCR2 Q8TDQ0 1/20 0.33
▸ BDKRB2 P30411 4/20 0.32
▸ ADORA3 P0DMS8 1/20 0.32
▸ ALDH1A1 P00352 4/20 0.31
▸ HSD17B10 Q99714 3/20 0.31
▸ GAA P10253 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ BRD4 O60885 2/20 0.31
▸ IMPDH2 P12268 1/20 0.31
▸ KDM4E B2RXH2 2/20 0.30
▸ HPGD P15428 2/20 0.30
▸ POLB P06746 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ HIF1A Q16665 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2597242 0.93 HAVCR2 (0.30) HAVCR2BDKRB2HSD17B10KDM4E
SCHEMBL2597260 0.92 IMPDH2 (0.33) HAVCR2BDKRB2ALDH1A1HSD17B10GAA
SCHEMBL2597178 0.92 KDM4E (0.31) ALDH1A1KDM4E
SCHEMBL2597118 0.92 CYP1A2 (0.33) ALDH1A1HSD17B10GAAKDM4EHPGD
SCHEMBL2597259 0.92 ALDH1A1 (0.33) ALDH1A1HSD17B10GAASMN1; SMN2IMPDH2
SCHEMBL2597234 0.91 KDM4E (0.34) ALDH1A1HSD17B10GAAKDM4EHPGD
SCHEMBL12180538 0.91 ALDH1A1 (0.33) HAVCR2BDKRB2ALDH1A1HPGDPOLB
SCHEMBL2597312 0.90 ADORA3 (0.32) ADORA3
SCHEMBL2597274 0.90 HAVCR2 (0.32) HAVCR2BRD4IMPDH2
SCHEMBL2597245 0.90 KDM4E (0.34) ALDH1A1HSD17B10GAAKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2571865-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES Novartis AG (CH) 2013-03-27 — — EP claimed
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG 2013-02-28 — — US claimed
WO-2011144666-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG (CH) 2011-11-24 — — WO claimed
EP-2571865-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES Novartis AG (CH) 2013-03-27 — — EP disclosed
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG 2013-02-28 — — US disclosed
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG 2013-02-28 — — US disclosed
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG 2013-02-28 — — US disclosed
WO-2011144666-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG (CH) 2011-11-24 — — WO disclosed
WO-2011144666-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES NOVARTIS AG (CH) 2011-11-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053381-A1 2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES GRIK2, GRIK1, GRIK4 HAVCR2 4470/4885BDKRB2 369/4885ADORA3 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.